Related Experiment Video
Updated: Aug 12, 2026

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody
Tiziana Piazza1, Emanuela Cha, Italia Bongarzone
1Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.
Insights
Researchers developed a novel single-chain antibody fragment (scFv) targeting Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166). This scFv facilitates targeted delivery of immunotoxins into tumor cells, demonstrating its potential for cancer therapy.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) is an immunoglobulin superfamily member involved in cell-cell interactions.
- ALCAM/CD166 plays a role in various biological processes, including immune responses and cancer progression.
Purpose of the Study:
- To develop and characterize a fully human single-chain antibody fragment (scFv) targeting ALCAM/CD166.
- To investigate the potential of this scFv for targeted cancer therapy through immunotoxin delivery.
Main Methods:
- Phage display library selection and cell panning to isolate the I/F8 scFv.
- Mass spectrometry (MALDI-TOF) for protein identification.
- Binding assays, internalization studies, and immunofluorescence microscopy.
Main Results:
- The I/F8 scFv specifically binds to ALCAM/CD166 across human, monkey, and murine species.
- I/F8 scFv binding induces ALCAM/CD166 internalization via a clathrin-dependent pathway.
- ALCAM/CD166-I/F8 complexes are recycled to the cell surface.
- I/F8 scFv-saporin immunoconjugates selectively kill ALCAM/CD166-expressing tumor cells.
Conclusions:
- The I/F8 scFv is a promising tool for functional studies of ALCAM/CD166.
- The I/F8 scFv enables efficient intracellular delivery of effector moieties for targeted cancer therapy.
Abstract:
Activated leukocyte cell adhesion molecule (ALCAM/CD166), a member of the immunoglobulin superfamily with five extracellular immunoglobulin-like domains, promotes heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. Here we describe a fully human single-chain antibody fragment (scFv) directed to ALCAM/CD166. We selected the I/F8 scFv from a phage display library of human V-gene segments by cell panning and phage internalization into IGROV-I human ovary carcinoma cells. The I/F8 specificity was identified as ALCAM/CD166 by matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) peptide mass fingerprinting of the I/F8-immunoprecipitated protein. The I/F8 scFv reacts with the human, monkey and murine ALCAM/CD166 molecule, indicating that the recognized epitope is highly conserved. The I/F8 scFv completely abolished binding of both ALCAM/Fc and CD6/Fc soluble ligands, whereas it did not compete with the anti-ALCAM/CD166 murine monoclonal antibodies J4-81 and 3A6 and therefore recognizes a different epitope. Engagement through I/F8 scFv, 3A6 monoclonal antibody or CD6/Fc ligand induced ALCAM/CD166 internalization, with a kinetics slower than that of transferrin in the same cells. Newly internalized I/F8-ALCAM complexes colocalized with clathrin but not with caveolin and we demonstrated, using surface biotinylation and recycling assays, that endocytosed ALCAM/CD166 recycles back to the cell surface. Such an endocytic pathway allows the efficient delivery of an I/F8 scFv-saporin immunotoxin into tumor cells, as the conjugates are able to selectively kill cell lines expressing ALCAM/CD166. Altogether these data provide evidence of the suitability of the I/F8 scFv for further functional analysis of ALCAM/CD166 and intracellular delivery of effector moieties.
More Related Videos
09:07Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations
Published on: August 22, 2019
10:35Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
Published on: February 5, 2021